By physician referral or invitation only

Merck Crohn's

To evaluate the efficacy of tulisokibart compared with placebo as assessed by the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (<150) at Week 52

Age & Gender

18 years ~ 75 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

North Carolina (Statewide)

Additional Study Information

Principal Investigator

Millie Long
Center for Gastrointestinal Biology and Disease

Study Type

Clinical or Medical
Interventional

Study Topics

Stomach, Digestion and Gut Health

IRB Number

24-2319

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.